{"id":"intravenous-amiodarone-1","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Hypotension"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Phlebitis at injection site"},{"rate":"5-10","effect":"Nausea"},{"rate":"1-5","effect":"Pulmonary toxicity (chronic use)"},{"rate":"5-10","effect":"Thyroid dysfunction (chronic use)"},{"rate":"1-3","effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1083993","moleculeType":"Small molecule","molecularWeight":"681.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amiodarone is a Class III antiarrhythmic agent with properties of all four Vaughan-Williams classes. It prolongs the action potential duration and refractory period by blocking potassium channels, while also inhibiting sodium and calcium channels and beta-adrenergic receptors. This multi-channel blockade makes it effective for suppressing both atrial and ventricular arrhythmias.","oneSentence":"Intravenous amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to suppress abnormal electrical activity and restore normal heart rhythm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:43.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute conversion of atrial fibrillation to normal sinus rhythm"},{"name":"Suppression of life-threatening ventricular arrhythmias"},{"name":"Maintenance of normal sinus rhythm in patients with atrial fibrillation"}]},"trialDetails":[{"nctId":"NCT05524077","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2020-07-08","conditions":"Heart Disease Structural Disorder, Ventricular Tachycardia, Cardiomyopathy, Dilated","enrollment":162},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":"Acute Aluminum Phosphide Poisoned Cases","enrollment":74},{"nctId":"NCT04844801","phase":"NA","title":"Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-11-09","conditions":"Supraventricular Arrhythmia, Septic Shock","enrollment":240},{"nctId":"NCT05549752","phase":"PHASE3","title":"Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia","status":"RECRUITING","sponsor":"Hippocration General Hospital","startDate":"2023-03-24","conditions":"Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia","enrollment":80},{"nctId":"NCT05445297","phase":"PHASE4","title":"Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter","status":"COMPLETED","sponsor":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","startDate":"2022-01-26","conditions":"Atrial Fibrillation Paroxysmal","enrollment":60},{"nctId":"NCT05391893","phase":"PHASE4","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2020-06-19","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":444},{"nctId":"NCT05169866","phase":"PHASE3","title":"Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2022-05-29","conditions":"New Onset Atrial Fibrillation, Complications; Cardiac, Postoperative","enrollment":274},{"nctId":"NCT04748991","phase":"PHASE3","title":"Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-09","conditions":"Atrial Fibrillation, Post-cardiac Surgery","enrollment":50},{"nctId":"NCT05287191","phase":"PHASE3","title":"MAGNAM Trial, Magnesium Versus Amiodarone in Atrial Fibrillation in Critical Care","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-01-05","conditions":"Atrial Fibrillation New Onset","enrollment":200},{"nctId":"NCT05004077","phase":"PHASE4","title":"Repeated Amiodarone Dosing In Cardiac surgicaL Procedures","status":"TERMINATED","sponsor":"Kevin W Hatton, MD, PhD","startDate":"2021-11-02","conditions":"Atrial Fibrillation","enrollment":3},{"nctId":"NCT04392921","phase":"NA","title":"Prophylaxis for Patients at Risk to Eliminate Post-operative Atrial Fibrillation","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-03-07","conditions":"Atrial Fibrillation","enrollment":80},{"nctId":"NCT04234906","phase":"PHASE4","title":"Prevention of Post-Operative Cardiac Arrhythmias","status":"UNKNOWN","sponsor":"Jeffrey Moak","startDate":"2023-01","conditions":"Cardiac; Dysrhythmia, Postoperative, Congenital Heart Surgery","enrollment":870},{"nctId":"NCT04092621","phase":"PHASE4","title":"Rapid Atrial Fibrillation Treatment Strategy","status":"UNKNOWN","sponsor":"Our Lady of the Lake Hospital","startDate":"2019-09-16","conditions":"New Onset Atrial Fibrillation, Sepsis, Respiratory Failure","enrollment":40},{"nctId":"NCT02668432","phase":"PHASE4","title":"Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-05","conditions":"New Onset Atrial Fibrillation, Severe Sepsis, Septic Shock","enrollment":9},{"nctId":"NCT03432663","phase":"PHASE4","title":"Time-dependent Amiodarone Treatment in Atrial Fibrillation","status":"COMPLETED","sponsor":"Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud","startDate":"2008-08-01","conditions":"Atrial Fibrillation","enrollment":60},{"nctId":"NCT01477983","phase":"PHASE4","title":"Kansai Plus Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2011-11","conditions":"Atrial Fibrillation","enrollment":2113},{"nctId":"NCT02025465","phase":"PHASE4","title":"Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2013-12","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":150},{"nctId":"NCT01401647","phase":"PHASE3","title":"Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation or Tachycardia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-05","conditions":"Cardiac Arrest","enrollment":3024},{"nctId":"NCT00383799","phase":"PHASE4","title":"Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia","status":"TERMINATED","sponsor":"Hospital General Universitario Gregorio Marañon","startDate":"2005-09","conditions":"Ventricular Tachycardia, Wide QRS Tachycardia","enrollment":302},{"nctId":"NCT02114528","phase":"PHASE4","title":"Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention","status":"TERMINATED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2014-10","conditions":"Ventricular Tachycardia, Ventricular Arrhythmia","enrollment":40},{"nctId":"NCT02307591","phase":"PHASE2, PHASE3","title":"Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)","status":"WITHDRAWN","sponsor":"Emergency NGO Onlus","startDate":"2014-12","conditions":"Ebola Virus Disease","enrollment":""},{"nctId":"NCT00121524","phase":"PHASE2","title":"Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome","status":"COMPLETED","sponsor":"Petter Andreas Steen","startDate":"2003-01","conditions":"Cardiac Arrest","enrollment":904},{"nctId":"NCT00816192","phase":"NA","title":"Comparison of Externally Versus Internally Cooled Tip Catheter Ablation in Paroxysmal Atrial Fibrillation","status":"TERMINATED","sponsor":"University Hospital, Bordeaux","startDate":"2008-12","conditions":"Atrial Fibrillation","enrollment":86}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["24 hour amiodarone"],"phase":"marketed","status":"active","brandName":"Intravenous amiodarone(1)","genericName":"Intravenous amiodarone(1)","companyName":"Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud","companyId":"instituto-de-cardiolog-a-y-medicina-vascular-hospital-zambrano-hellion-tec-salud","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to suppress abnormal electrical activity and restore normal heart rhythm. Used for Acute conversion of atrial fibrillation to normal sinus rhythm, Suppression of life-threatening ventricular arrhythmias, Maintenance of normal sinus rhythm in patients with atrial fibrillation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}